{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:59:37Z","timestamp":1782014377855,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.leukres.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T20:30:04Z","timestamp":1531254604000},"page":"75-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells"],"prefix":"10.1016","volume":"71","author":[{"given":"Kiyoyuki","family":"Ogata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Sei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Saft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo G. Della","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.07.009_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.009_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.18632\/oncotarget.185","article-title":"Standards and impact of hematopathology in myelodysplastic syndromes (MDS)","volume":"1","author":"Valent","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.07.009_bib0015","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2018.07.009_bib0020","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.009_bib0025","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.leukres.2013.10.007","article-title":"Current pathology practices in and barriers to MDS diagnosis","volume":"37","author":"Glauser","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.009_bib0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3324\/haematol.2013.084418","article-title":"Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?","volume":"98","author":"Bennett","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.07.009_bib0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.009_bib0040","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2005-12-4916","article-title":"Diagnostic application of flow cytometric characteristics of CD34 + cells in low-grade myelodysplastic syndromes","volume":"108","author":"Ogata","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.009_bib0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.leukres.2007.04.020","article-title":"Flow cytometry in myelodysplastic syndromes: report from a working conference","volume":"32","author":"Loken","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.009_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.leukres.2007.07.008","article-title":"Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?","volume":"32","author":"van de Loosdrecht","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.009_bib0055","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2009.008532","article-title":"Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Supplementary infromation","volume":"94","author":"Ogata","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.07.009_bib0060","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2011.048421","article-title":"Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study","volume":"97","author":"Della Porta","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.07.009_bib0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.leu.2403680","article-title":"Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome","volume":"19","author":"Malcovati","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.009_bib0070","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/leu.2008.49","article-title":"The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+hematopoietic cells allows discrimination between normal\/reactive and myelodysplastic syndrome precursors","volume":"22","author":"Matarraz","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.009_bib0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cyto.b.21233","article-title":"Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube","volume":"88","author":"Rajab","year":"2015","journal-title":"Cytom. B - Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.07.009_bib0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2010.08146.x","article-title":"Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes","volume":"149","author":"Xu","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.07.009_bib0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2015.11.013","article-title":"Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias","volume":"54","author":"Cremers","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2018.07.009_bib0090","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1002\/cncr.25353","article-title":"Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome","volume":"116","author":"Kern","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2018.07.009_bib0095","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3324\/haematol.2014.112755","article-title":"Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric ogata score in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Bardet","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.07.009_bib0100","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/leu.2013.178","article-title":"Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes","volume":"27","author":"Mathis","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.leukres.2018.07.009_bib0105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ijlh.12700","article-title":"A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes","volume":"39","author":"K\u00e1rai","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2018.07.009_bib0110","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0145-2126(17)30269-2","article-title":"Flow cytometry \u201cOgata score\u201d in latin America. On behalf of the grupo latinoamericano De mielodisplasia (GLAM)","volume":"55","author":"Grille","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.009_bib0115","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2014.191","article-title":"Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes - proposal from the International\/European LeukemiaNet working group for flow cytometry in MDS","volume":"28","author":"Porwit","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.009_bib0120","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.009_bib0125","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cyto.a.22995","article-title":"Elimination of erroneous results in flow cytometry caused by antibody binding to Fc receptors on human monocytes and macrophages","volume":"89","author":"Andersen","year":"2016","journal-title":"Cytom. A"},{"key":"10.1016\/j.leukres.2018.07.009_bib0130","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2009.005801","article-title":"Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes","volume":"94","author":"Van De Loosdrecht","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.07.009_bib0135","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2012.30","article-title":"Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet working group","volume":"26","author":"Westers","year":"2012","journal-title":"Leukemia."},{"key":"10.1016\/j.leukres.2018.07.009_bib0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.leukres.2007.08.022","article-title":"Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes","volume":"32","author":"Satoh","year":"2008","journal-title":"Leuk. Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261830153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T11:34:16Z","timestamp":1571571256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261830153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":28,"alternative-id":["S014521261830153X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}